pemigatinib   Click here for help

GtoPdb Ligand ID: 9767

Synonyms: example 126 [WO2014007951] | INCB 54828 | INCB-54828 | INCB054828 | INCB54828 | Pemazyre®
Approved drug PDB Ligand
pemigatinib is an approved drug (FDA (2020), EMA (2021))
Compound class: Synthetic organic
Comment: Pemigatinib (INCB54828) is a FGFR inhibitor claimed in Incyte Corporation's patent WO2014007951 [3]. It is equipotent at FGFR subtypes 1-3 [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

pemigatinib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 83.16
Molecular weight 487.2
XLogP 2.02
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCN1C(=O)N(Cc2c1c1cc([nH]c1nc2)CN1CCOCC1)c1c(F)c(OC)cc(c1F)OC
Isomeric SMILES CCN1C(=O)N(Cc2c1c1cc([nH]c1nc2)CN1CCOCC1)c1c(F)c(OC)cc(c1F)OC
InChI InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)
InChI Key HCDMJFOHIXMBOV-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Pemigatinib (INCB54828) progressed to Phase 3 cancer clinical trials. Click here to see all INCB54828 trials registered with ClinicalTrials.gov. In April 2020 the FDA approved the use of pemigatinib as a treatment for locally advanced/metastatic cholangiocarcinoma with a verified fibroblast growth factor receptor 2 (FGFR2) fusion [4] or other rearrangement [2]. It is indicated for tumours that have been previously treated and which cannot be resected. Pemigatinib was granted EMA orphan designations for myeloid/lymphoid neoplasms (MLNs) with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 (2019) and cholangiocarcinoma (2018). Full EMA approval (to treat cholangiocarcinoma) was issued in March 2021. In August 2022, FDA approval was expanded to include treatment of relapsed/refractory MLNs with FGFR1 rearrangement.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Pemigatinib inhibits aberrant FGFR-related signal transduction activation in FGFR1/2/3-overexpressing tumour cells and thereby inhibits cancer cell proliferation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02924376 Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) Phase 2 Interventional Incyte Corporation 1